Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Inclusion Criteria:

• Subjects with insulin requiring type 1 or type 2 diabetes for at least 24 months

• Current treatment with human insulin (either premix of short and long/intermediateacting insulin) in a twice daily treatment regimen preparation and/or self-mix for atleast 12 months

• Body mass index (BMI) below or equal to 35.0 kg/m^2

• HbA1c below or equal to 11.0%

Exclusion Criteria:

• Total daily insulin dose at least 1.4 IU/kg

• Treatment with oral hypoglycaemic agents within the month prior to inclusion

• Recurrent severe hypoglycaemia (as judged by the investigator)

• Active proliferative retinopathy

• Impaired renal function with creatinine at least 150 mcmol/l (1.7 mg/dl)

• History of pancreatitis